Novocure (NSDQ:NVCR) today touted the results of a retrospective sub-group analysis of its EF-14 Phase III pivotal trial in patients with newly diagnosed glioblastoma. The analysis, which was published in the Journal of Neuro-Oncology, demonstrated that more time on Novocure’s Optune device predicted increased survival in people who received Optune plus temozolomide compared to those who received […]
Boston Scientific puts $4B on the table for BTG’s interventional portfolio
Boston Scientific (NYSE:BSX) said today that it agreed to offer $4.24 billion to acquire British medical device maker BTG (LON:BTG) and its portfolio of interventional drug-device therapies. The Marlborough, Mass.-based company said that its acquisition of BTG will augment Boston Scientific’s capabilities in the treatment of cancer and pulmonary embolism. “We are confident that the addition of these therapies […]
OncoSec shares fall on preliminary data from skin cancer trial
Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable, advanced melanoma. OncoSec’s lead product, Tavo, uses electroporation to deliver IL-12 directly into a patient’s tumor, triggering an immune response. As of Sept. 1, 21 people […]
Mustang Bio studies intraventricular delivery of immunotherapy in Ph1 trial
Mustang Bio (NSDQ:MBIO) said today that it launched a Phase I trial to evaluate the safety and efficacy of intraventricular delivery of CAR T-cells to the brains of people with HER2-positive breast cancer. The 21-patient trial’s primary goal is to determine the recommended dosing regimen for a Phase II trial. Secondary objectives include evaluating the […]
Delcath registers $100m offering
Delcath Systems (NSDQ:DCTH) registered a $100 million offering with the SEC this week to support the development of its system designed to administer high-dose chemotherapy to the liver. The company’s product, melphalan hydrochloride for injection for use with the Delcath hepatic delivery system, won CE Mark clearance in Europe in 2012 and is under consideration by […]
Researchers develop nanodevice to deliver immunotherapy
Researchers at Houston Methodist Research Institute have created a nanodevice that can be used to deliver immunotherapy to treat triple-negative breast cancer. The tiny device is designed to be inserted directly into a tumor, delivering a localized, sustained-release dose of therapy and eliminating the need for patients to undergo IV treatments. The scientists described their […]
NovoCure slides on Q3 sales miss
NovoCure (NSDQ:NVCR) shares took a hit today, despite lower-than-forecast losses, after the company reported financial results that missed expectations for third-quarter sales. NVCR shares were down-12.7% to $36.23 today in late-morning trading on the news. Get the full story on our sister site, MassDevice.com.
U.S. military to adopt Adaptiiv’s 3D bolus cancer software
Adaptiiv Medical Technologies said that the U.S. military will use its 3D bolus software to treat American veterans with cancer at Walter Reed National Military Medical Center. Adaptiiv designed its software to convert patient CT scan data into a digital model that can be used to print a bolus that conforms to patient anatomy, according to […]
Novocure touts Phase II pancreatic cancer pilot study
Novocure (NSDQ:NVCR) today touted the results of a Phase II pilot trial designed to test the feasibility, safety and efficacy of its Tumor Treating Fields therapy in patients with unresectable, advanced pancreatic cancer. The St. Helier, N.J.-based company’s Optune device uses electric fields, called Tumor Treating Fields, to disrupt cell division, inhibit tumor growth and trigger […]
Nanobiotix reels in $18.5m tranche from European Investment Bank
Nanobiotix (PAR:NANO.PA) received €16 million ($18.5 million) in the first tranche of a previously-announced non-dilutive loan from the European Investment Bank. The five-year funding deal is designed to support the company’s development of nanoparticle-based cancer therapies. Nanobiotix is specifically charged with bringing its NBTXR3 product through a clinical development program in patients with head and neck […]
- 1
- 2
- 3
- …
- 25
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn